TY - JOUR
T1 - Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer
AU - Liu, Yanhong
AU - Lusk, Christine M.
AU - Cho, Michael H.
AU - Silverman, Edwin K.
AU - Qiao, Dandi
AU - Zhang, Ruyang
AU - Scheurer, Michael E.
AU - Kheradmand, Farrah
AU - Wheeler, David A.
AU - Tsavachidis, Spiridon
AU - Armstrong, Georgina
AU - Zhu, Dakai
AU - Wistuba, Ignacio I.
AU - Chow, Chi Wan B.
AU - Behrens, Carmen
AU - Pikielny, Claudio W.
AU - Neslund-Dudas, Christine
AU - Pinney, Susan M.
AU - Anderson, Marshall
AU - Kupert, Elena
AU - Bailey-Wilson, Joan
AU - Gaba, Colette
AU - Mandal, Diptasri
AU - You, Ming
AU - de Andrade, Mariza
AU - Yang, Ping
AU - Field, John K.
AU - Liloglou, Triantafillos
AU - Davies, Michael
AU - Lissowska, Jolanta
AU - Swiatkowska, Beata
AU - Zaridze, David
AU - Mukeriya, Anush
AU - Janout, Vladimir
AU - Holcatova, Ivana
AU - Mates, Dana
AU - Milosavljevic, Sasa
AU - Scelo, Ghislaine
AU - Brennan, Paul
AU - McKay, James
AU - Liu, Geoffrey
AU - Hung, Rayjean J.
AU - Christiani, David C.
AU - Schwartz, Ann G.
AU - Amos, Christopher I.
AU - Spitz, Margaret R.
N1 - Publisher Copyright:
© 2018 International Association for the Study of Lung Cancer
PY - 2018/10
Y1 - 2018/10
N2 - Background: Genome-wide association studies are widely used to map genomic regions contributing to lung cancer (LC) susceptibility, but they typically do not identify the precise disease-causing genes/variants. To unveil the inherited genetic variants that cause LC, we performed focused exome-sequencing analyses on genes located in 121 genome-wide association study–identified loci previously implicated in the risk of LC, chronic obstructive pulmonary disease, pulmonary function level, and smoking behavior. Methods: Germline DNA from 260 case patients with LC and 318 controls were sequenced by utilizing VCRome 2.1 exome capture. Filtering was based on enrichment of rare and potential deleterious variants in cases (risk alleles) or controls (protective alleles). Allelic association analyses of single-variant and gene-based burden tests of multiple variants were performed. Promising candidates were tested in two independent validation studies with a total of 1773 case patients and 1123 controls. Results: We identified 48 rare variants with deleterious effects in the discovery analysis and validated 12 of the 43 candidates that were covered in the validation platforms. The top validated candidates included one well-established truncating variant, namely, BRCA2, DNA repair associated gene (BRCA2) K3326X (OR = 2.36, 95% confidence interval [CI]: 1.38–3.99), and three newly identified variations, namely, lymphotoxin beta gene (LTB) p.Leu87Phe (OR = 7.52, 95% CI: 1.01–16.56), prolyl 3-hydroxylase 2 gene (P3H2) p.Gln185His (OR = 5.39, 95% CI: 0.75–15.43), and dishevelled associated activator of morphogenesis 2 gene (DAAM2) p.Asp762Gly (OR = 0.25, 95% CI: 0.10–0.79). Burden tests revealed strong associations between zinc finger protein 93 gene (ZNF93), DAAM2, bromodomain containing 9 gene (BRD9), and the gene LTB and LC susceptibility. Conclusion: Our results extend the catalogue of regions associated with LC and highlight the importance of germline rare coding variants in LC susceptibility.
AB - Background: Genome-wide association studies are widely used to map genomic regions contributing to lung cancer (LC) susceptibility, but they typically do not identify the precise disease-causing genes/variants. To unveil the inherited genetic variants that cause LC, we performed focused exome-sequencing analyses on genes located in 121 genome-wide association study–identified loci previously implicated in the risk of LC, chronic obstructive pulmonary disease, pulmonary function level, and smoking behavior. Methods: Germline DNA from 260 case patients with LC and 318 controls were sequenced by utilizing VCRome 2.1 exome capture. Filtering was based on enrichment of rare and potential deleterious variants in cases (risk alleles) or controls (protective alleles). Allelic association analyses of single-variant and gene-based burden tests of multiple variants were performed. Promising candidates were tested in two independent validation studies with a total of 1773 case patients and 1123 controls. Results: We identified 48 rare variants with deleterious effects in the discovery analysis and validated 12 of the 43 candidates that were covered in the validation platforms. The top validated candidates included one well-established truncating variant, namely, BRCA2, DNA repair associated gene (BRCA2) K3326X (OR = 2.36, 95% confidence interval [CI]: 1.38–3.99), and three newly identified variations, namely, lymphotoxin beta gene (LTB) p.Leu87Phe (OR = 7.52, 95% CI: 1.01–16.56), prolyl 3-hydroxylase 2 gene (P3H2) p.Gln185His (OR = 5.39, 95% CI: 0.75–15.43), and dishevelled associated activator of morphogenesis 2 gene (DAAM2) p.Asp762Gly (OR = 0.25, 95% CI: 0.10–0.79). Burden tests revealed strong associations between zinc finger protein 93 gene (ZNF93), DAAM2, bromodomain containing 9 gene (BRD9), and the gene LTB and LC susceptibility. Conclusion: Our results extend the catalogue of regions associated with LC and highlight the importance of germline rare coding variants in LC susceptibility.
KW - Exome sequencing
KW - Lung cancer
KW - Rare variants
KW - Susceptibility loci
UR - http://www.scopus.com/inward/record.url?scp=85051695595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051695595&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2018.06.016
DO - 10.1016/j.jtho.2018.06.016
M3 - Article
C2 - 29981437
AN - SCOPUS:85051695595
SN - 1556-0864
VL - 13
SP - 1483
EP - 1495
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 10
ER -